Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Non-Current Deffered Revenue (2023 - 2024)

Historic Non-Current Deffered Revenue for Connect Biopharma Holdings (CNTB) over the last 2 years, with Q4 2024 value amounting to $632000.0.

  • Connect Biopharma Holdings' Non-Current Deffered Revenue rose 5604.94% to $632000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $632000.0, marking a year-over-year increase of 5604.94%. This contributed to the annual value of $632000.0 for FY2024, which is 5604.94% up from last year.
  • According to the latest figures from Q4 2024, Connect Biopharma Holdings' Non-Current Deffered Revenue is $632000.0, which was up 5604.94% from $405000.0 recorded in Q4 2023.
  • Connect Biopharma Holdings' 5-year Non-Current Deffered Revenue high stood at $632000.0 for Q4 2024, and its period low was $405000.0 during Q4 2023.